NASDAQ:RDHL - REDHILL BIOPHAR/S Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding REDHILL BIOPHAR/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $6.09 -0.11 (-1.77 %) (As of 12/12/2019 02:20 PM ET) Add Compare Today's Range$6.06Now: $6.09▼$6.2750-Day Range$5.75MA: $6.49▼$7.7252-Week Range$5.13Now: $6.09▼$9.20Volume81,611 shsAverage Volume255,195 shsMarket Capitalization$133.61 millionP/E RatioN/ADividend YieldN/ABeta1.33 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:RDHL Previous Symbol CUSIPN/A CIK1553846 Webhttp://www.redhillbio.com/ Phone972-3541-3131Debt Debt-to-Equity Ratio0.13 Current Ratio2.22 Quick Ratio2.08Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$8.36 million Price / Sales15.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.41 per share Price / Book2.53Profitability EPS (Most Recent Fiscal Year)($1.70) Net Income$-38,820,000.00 Net Margins-631.96% Return on Equity-103.63% Return on Assets-72.78%Miscellaneous Employees75 Outstanding Shares21,940,000Market Cap$133.61 million Next Earnings Date2/25/2020 (Estimated) OptionableOptionable Receive RDHL News and Ratings via Email Sign-up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:RDHL Rates by TradingView REDHILL BIOPHAR/S (NASDAQ:RDHL) Frequently Asked Questions What is REDHILL BIOPHAR/S's stock symbol? REDHILL BIOPHAR/S trades on the NASDAQ under the ticker symbol "RDHL." How were REDHILL BIOPHAR/S's earnings last quarter? REDHILL BIOPHAR/S (NASDAQ:RDHL) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.50). The biotechnology company earned $2.45 million during the quarter, compared to analyst estimates of $2.14 million. REDHILL BIOPHAR/S had a negative return on equity of 103.63% and a negative net margin of 631.96%. View REDHILL BIOPHAR/S's Earnings History. When is REDHILL BIOPHAR/S's next earnings date? REDHILL BIOPHAR/S is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for REDHILL BIOPHAR/S. What price target have analysts set for RDHL? 4 Wall Street analysts have issued 12-month price objectives for REDHILL BIOPHAR/S's stock. Their forecasts range from $17.00 to $24.00. On average, they expect REDHILL BIOPHAR/S's stock price to reach $20.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price. View Analyst Price Targets for REDHILL BIOPHAR/S. What is the consensus analysts' recommendation for REDHILL BIOPHAR/S? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for REDHILL BIOPHAR/S in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for REDHILL BIOPHAR/S. Has REDHILL BIOPHAR/S been receiving favorable news coverage? News coverage about RDHL stock has been trending very negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. REDHILL BIOPHAR/S earned a daily sentiment score of -3.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for REDHILL BIOPHAR/S. Are investors shorting REDHILL BIOPHAR/S? REDHILL BIOPHAR/S saw a increase in short interest in October. As of October 15th, there was short interest totalling 461,800 shares, an increase of 9.1% from the September 15th total of 423,200 shares. Based on an average daily trading volume, of 68,800 shares, the days-to-cover ratio is presently 6.7 days. Approximately 1.8% of the shares of the company are sold short. View REDHILL BIOPHAR/S's Current Options Chain. Who are some of REDHILL BIOPHAR/S's key competitors? Some companies that are related to REDHILL BIOPHAR/S include RAPT Therapeutics (RAPT), Provention Bio (PRVB), Emisphere Technologies (EMIS), Prothena (PRTA), Magenta Therapeutics (MGTA), Morphic (MORF), Stemline Therapeutics (STML), Dermira (DERM), Crinetics Pharmaceuticals (CRNX), Frequency Therapeutics (FREQ), MacroGenics (MGNX), Akorn (AKRX), Organogenesis (ORGO), Sinovac Biotech (SVA) and Ardelyx (ARDX). What other stocks do shareholders of REDHILL BIOPHAR/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other REDHILL BIOPHAR/S investors own include Agenus (AGEN), Aralez Pharmaceuticals (ARLZ), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Sorrento Therapeutics (SRNE), Verastem (VSTM), Cara Therapeutics (CARA), Sangamo Therapeutics (SGMO) and Protalix Biotherapeutics (PLX). Who are REDHILL BIOPHAR/S's key executives? REDHILL BIOPHAR/S's management team includes the folowing people: Mr. Dror Ben-Asher, Co-Founder, Chairman & CEO (Age 53)Mr. Micha Ben-Chorin, Chief Financial Officer (Age 50)Mr. Gilead Raday, Chief Operating Officer (Age 44)Mr. Adi Frish, Sr. VP of Bus. Devel. & Licensing (Age 49)Mr. Guy Goldberg, Chief Bus. Officer (Age 43) Who are REDHILL BIOPHAR/S's major shareholders? REDHILL BIOPHAR/S's stock is owned by a number of of retail and institutional investors. Top institutional investors include Ibex Investors LLC (8.46%), Disciplined Growth Investors Inc. MN (5.22%), CLARET ASSET MANAGEMENT Corp (0.34%), Boston Partners (0.12%) and Millennium Management LLC (0.08%). Which institutional investors are selling REDHILL BIOPHAR/S stock? RDHL stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Ibex Investors LLC. Which institutional investors are buying REDHILL BIOPHAR/S stock? RDHL stock was bought by a variety of institutional investors in the last quarter, including Boston Partners, CLARET ASSET MANAGEMENT Corp and Disciplined Growth Investors Inc. MN. How do I buy shares of REDHILL BIOPHAR/S? Shares of RDHL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is REDHILL BIOPHAR/S's stock price today? One share of RDHL stock can currently be purchased for approximately $6.15. How big of a company is REDHILL BIOPHAR/S? REDHILL BIOPHAR/S has a market capitalization of $134.93 million and generates $8.36 million in revenue each year. The biotechnology company earns $-38,820,000.00 in net income (profit) each year or ($1.70) on an earnings per share basis. REDHILL BIOPHAR/S employs 75 workers across the globe.View Additional Information About REDHILL BIOPHAR/S. What is REDHILL BIOPHAR/S's official website? The official website for REDHILL BIOPHAR/S is http://www.redhillbio.com/. How can I contact REDHILL BIOPHAR/S? REDHILL BIOPHAR/S's mailing address is 21 HA`ARBA`A STREET, TEL AVIV L3, 64739. The biotechnology company can be reached via phone at 972-3541-3131. MarketBeat Community Rating for REDHILL BIOPHAR/S (NASDAQ RDHL)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 369 (Vote Outperform)Underperform Votes: 249 (Vote Underperform)Total Votes: 618MarketBeat's community ratings are surveys of what our community members think about REDHILL BIOPHAR/S and other stocks. Vote "Outperform" if you believe RDHL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDHL will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2019 by MarketBeat.com StaffFeatured Article: How to read a candlestick chart
